Zydus Presents Positive Phase 3 Saroglitazar Subgroup Data in PBC
Zydus Lifesciences Ltd 路 Press Release 路 12 Oct 2026, 11:30 pm
Zydus Presents Positive Phase 3 Saroglitazar Subgroup Data in PBC Zydus Lifesciences' subsidiary, Zydus Therapeutics, presented post hoc Phase 3 EPICS-III trial data for Saroglitazar in primary biliary cholangitis on 12th Oct'26. The drug demonstrated superior composite biochemical response versus placebo in both U.S. (60.7% vs. 0%; treatment difference 螖 60.7%) and non-U.S. subgroups (55.1% vs. 13.5%; 螖 41.6%). Saroglitazar was well tolerated and is currently under US FDA review, with Orphan Drug and Fast Track designations. Upon approval, Zydus plans to launch the drug in the U.S. by Mar'27.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- Press Release 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Press Release 路 04 Nov 2026
